Definium Therapeutics (DFTX) Cash & Current Investments (2020 - 2026)

Definium Therapeutics (DFTX) has 7 years of Cash & Current Investments data on file, last reported at $368.1 million in Q1 2026.

• Quarterly Cash & Current Investments rose 75.3% year-over-year to $368.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $368.1 million (up 75.3% YoY) and the FY2025 annual result came in at $409.1 million, up 50.67% from the prior year.
• Cash & Current Investments declined to $368.1 million in Q1 2026 per DFTX's latest filing, from $409.1 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $409.1 million in Q4 2025 and bottomed at $99.7 million in Q4 2023.
• The 5-year median for Cash & Current Investments is $196.0 million (2025), against an average of $204.8 million.
• The widest annual swing landed in 2022, when Cash & Current Investments tumbled 32.66%; it then jumped 172.31% in 2024.
• Tracing DFTX's Cash & Current Investments over 5 years: stood at $131.7 million in 2022, then fell by 24.29% to $99.7 million in 2023, then jumped by 172.31% to $271.5 million in 2024, then soared by 50.67% to $409.1 million in 2025, then retreated by 10.01% to $368.1 million in 2026.
• Per Business Quant, the three latest DFTX Cash & Current Investments figures stand at $368.1 million (Q1 2026), $409.1 million (Q4 2025), and $209.1 million (Q3 2025).

Peer Comparison